Compare ACLS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | RCUS |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2000 | 2018 |
| Metric | ACLS | RCUS |
|---|---|---|
| Price | $81.49 | $23.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $98.80 | $29.38 |
| AVG Volume (30 Days) | 505.2K | ★ 2.1M |
| Earning Date | 02-09-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.25 | N/A |
| Revenue | ★ $853,135,000.00 | $240,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $19.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.40 | $6.50 |
| 52 Week High | $102.93 | $26.40 |
| Indicator | ACLS | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 53.76 |
| Support Level | $82.02 | $21.80 |
| Resistance Level | $84.35 | $23.49 |
| Average True Range (ATR) | 3.36 | 1.18 |
| MACD | -0.56 | -0.25 |
| Stochastic Oscillator | 9.83 | 47.60 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.